From Biogen and Eisai: Lecanemab Confirmatory Phase 3 Clarity Met Primary Endpoint for Early Alzheimer’s Disease  

Biogen & Eisai Co and Early Alzheimer's Disease 
From Tokyo and Cambridge, Eisai Co., Ltd. and Biogen Inc. (BIIB) announced positive topline results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab. The product is an investigational anti-amyloid beta () protofibril antibody for the treatment of mild cognitive impairment (

This content is for paid subscribers.
Please click here to subscribe or here to log in.